BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34408597)

  • 1. The incidences of other primary cancers in patients with mycosis fungoides and Sézary syndrome.
    Błażewicz I; Olszewska B; Stawczyk-Macieja M; Jaśkiewicz M; Nowicki RJ; Sokołowska-Wojdyło M
    Postepy Dermatol Alergol; 2021 Apr; 38(2):289-294. PubMed ID: 34408597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument.
    McCaffrey S; Black RA; Nagao M; Sepassi M; Sharma G; Thornton S; Kim YH; Braverman J
    J Med Internet Res; 2019 Jan; 21(1):e11302. PubMed ID: 30617041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycosis fungoides and Sézary syndrome.
    Jonak C; Tittes J; Brunner PM; Guenova E
    J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
    Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
    J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part I: Clinical and histologic features and diagnosis.
    Stoll JR; Willner J; Oh Y; Pulitzer M; Moskowitz A; Horwitz S; Myskowski P; Noor SJ
    J Am Acad Dermatol; 2021 Nov; 85(5):1073-1090. PubMed ID: 33940098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
    Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
    Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-mycosis fungoides cutaneous lymphomas in a referral center in Taiwan: A retrospective case series and literature review.
    Liu KL; Tsai WC; Lee CH
    PLoS One; 2020; 15(1):e0228046. PubMed ID: 31978091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
    Molloy K; Jonak C; Woei-A-Jin FJSH; Guenova E; Busschots AM; Bervoets A; Hauben E; Knobler R; Porkert S; Fassnacht C; Cowan R; Papadavid E; Beylot-Barry M; Berti E; Alberti Violetti S; Estrach T; Matin R; Akilov O; Vakeva L; Prince M; Bates A; Bayne M; Wachsmuch R; Wehkamp U; Marschalko M; Servitje O; Turner D; Weatherhead S; Wobser M; Sanches JA; McKay P; Klemke D; Peng C; Howles A; Yoo J; Evison F; Scarisbrick J
    Br J Dermatol; 2020 Mar; 182(3):770-779. PubMed ID: 31049926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
    Bosisio FM; Cerroni L
    Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome (BIO-MUSE): Protocol for a Translational Study.
    Belfrage E; Ek S; Johansson Å; Brauner H; Sonesson A; Drott K
    JMIR Res Protoc; 2024 Apr; 13():e55723. PubMed ID: 38436589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary Cutaneous Lymphomas in Thailand: A 10-Year Retrospective Study.
    Pruksaeakanan C; Teyateeti P; Patthamalai P; Thumrongtharadol J; Chairatchaneeboon M
    Biomed Res Int; 2021; 2021():4057661. PubMed ID: 34235215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Tumor Microenvironment in Mycosis Fungoides and Sézary Syndrome.
    Liu Z; Wu X; Hwang ST; Liu J
    Ann Dermatol; 2021 Dec; 33(6):487-496. PubMed ID: 34858000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and Sézary syndrome (SS).
    Shalabi D; Bistline A; Alpdogan O; Kartan S; Mishra A; Porcu P; Nikbakht N
    Chin Clin Oncol; 2019 Feb; 8(1):11. PubMed ID: 30691274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome.
    Kawana Y; Suga H; Kamijo H; Miyagaki T; Sugaya M; Sato S
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycosis fungoides and Sézary syndrome in Japan. Clinicopathologic study of 107 autopsy cases.
    Arai E; Katayama I; Ishihara K
    Pathol Res Pract; 1991 May; 187(4):451-7. PubMed ID: 1876527
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.